Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD Source: Eur Respir J 2013; 42: 539-541 Year: 2013
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Effect of formoterol on exercise tolerance in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 214s Year: 2004
Effect of a single dose of formoterol and tiotropium in exercise tolerance in COPD patients: preliminary data Source: Eur Respir J 2003; 22: Suppl. 45, 405s Year: 2003
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 14s Year: 2005
Budesonide/formoterol improves exercise tolerance compared with placebo and formoterol in COPD patients Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance Year: 2009
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014
Combination therapy with maintenance budesonide and formoterol in COPD Source: Eur Respir J 2004; 24: 1070 Year: 2004
Rational timing of combination therapy with tiotropium and formoterol in moderate-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006
Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Effects of inhaled formoterol on dynamic hyperinflation during and after incremental treadmill exercise in patients with advanced COPD Source: Eur Respir J 2006; 28: Suppl. 50, 172s Year: 2006